COO: Financial results · Other company developments

ITEM 2.02. Results of Operations and Financial Condition. On June 4, 2026, The Cooper Companies, Inc. (the “Company”) issued a press release reporting results for its fiscal second quarter ended April 30, 2026. A copy of this release is attached and incorporated by reference. This information, including the exhibits(s) hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. The contents of any website or hyperlinks mentioned in the release are for informational purposes only and the contents thereof are not part of the release nor incorporated herein by reference. ITEM 8.01. Other Events. As described in its June 4, 2026 press release, the Company recorded a charge as further described below. In December 2023, CooperSurgical, one of the Company’s two business units, initiated a voluntary recall of three specific lots of CooperSurgical’s LifeGlobal TM global ® embryo culture media that it had produced. Subsequently, claims and lawsuits in various U.S. and international jurisdictions were brought by individuals who generally allege that they suffered damages associated with the use of the recalled product, including claims of embryo loss or reduced embryo viability. As of June 4, 2026, more than 140 lawsuits were filed, including three putative class actions (none of which has been certified), and over 1,500 claimants have been proffered to the Company. Between December 2023 and mid-March 2026, the Company resolved a significant number of claims and lawsuits through settlements which were largely covered